Previous 10 | Next 10 |
home / stock / esalf / esalf news
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024 TOKYO, Mar 29, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that drug discovery research conducted on lemborexant (brand name: Dayvigo), ...
2024-03-22 08:50:49 ET More on Biogen, Eisai Co., Ltd., etc. Biogen Inc. (BIIB) Stifel 2024 Virtual CNS Days (Transcript) Eisai: All About Lenvima And Leqembi Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen chief medical o...
Lifenet and Eisai Co-Develop Dementia Insurance "be" TOKYO, Mar 21, 2024 - (JCN Newswire) - LIFENET INSURANCE COMPANY and Eisai Co., Ltd. announced today that they have co-developed Dementia Insurance "be", a dementia insurance that supports early detection and treatment of dementia...
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace TOKYO, Mar 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been selected for the first time by the Ministry of Economy, Trade and Industry (METI) and...
2024-03-20 09:00:32 ET More on Labcorp Laboratory Corporation of America Holdings (LH) Q4 2023 Earnings Call Transcript Laboratory Corporation of America Holdings 2023 Q4 - Results - Earnings Call Presentation Labcorp introduces weight loss management portfolio ...
2024-03-17 07:26:15 ET Summary Don't be fooled by the high multiples for Eisai, since high probability growth is incoming. Lenvima and Leqembi should continue to deliver, and Eisai is well positioned with its strategic partnerships. Particularly, Leqembi, which is on the cusp ...
2024-03-07 09:59:39 ET More on Biogen Biogen Inc. (BIIB) TD Cowen 44th Annual Health Care Conference - (Transcript) Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade) Biogen Inc. (BIIB) Q4 2023 Earnings Call Transcript Biogen grant...
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer's Disease to Better Serve Patients TOKYO, Mar 6, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that its U.S. subsidiary Eisai Inc. has decided to invest up to 15 million USD in C2N Diagnostics LLC...
2024-02-22 17:03:07 ET More on Ligand Pharmaceuticals Johnson & Johnson posts Q4 beat as pharma and MedTech outperform FDA approves Ligand's Zelsuvmi for treatment of molluscum Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earni...
Eisai to Boost Initiatives on Greenhouse Gas Reduction, Aiming to Achieve Net Zero by 2050 TOKYO, Feb 21, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval to participate in the Japan Climate Initiative (JCI) Race to Zero Circle, which commits to ...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co Ltd Company Name:
ESALF Stock Symbol:
OTCMKTS Market:
Eisai's Antiepileptic Drug Fycompa Approved in China for Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures TOKYO, May 13, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received approval in China for the additional indication of its in-house disc...
Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) TOKYO, Apr 18, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that "The Research on Treatments for Alzheimer's Disease Ba...
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan TOKYO, Apr 17, 2024 - (JCN Newswire) - Eisai Co., Ltd. announced today that the injection formulation of its in-house discovered antiepileptic drug (AED) Fycompa (perampanel hydrate) for intravenous (IV) infu...